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Background: Due to significant limitations to the access to orthotropic liver transplantation, cell therapies for
liver diseases have gained large interest worldwide.
Scope of review: To revise current literature dealing with cell therapy for liver diseases. We discussed the ad-
vantages and pitfalls of the different cell sources tested so far in clinical trials and the rationale underlying the
potential benefits of transplantation of human biliary tree stem cells (hBTSCs).
Major conclusions: Transplantation of adult hepatocytes showed transient benefits but requires immune-sup-
pression that is a major pitfall in patients with advanced liver diseases. Mesenchymal stem cells and hemato-
poietic stem cells transplanted into patients with liver diseases are not able to replace resident hepatocytes but
rather they target autoimmune or inflammatory processes into the liver. Stem cells isolated from fetal or adult
liver have been recently proposed as alternative cell sources for advanced liver cirrhosis and metabolic liver
disease. We demonstrated the presence of multipotent cells expressing a variety of endodermal stem cell markers
in (peri)-biliary glands of bile ducts in fetal or adult human tissues, and in crypts of gallbladder epithelium. In
the first cirrhotic patients treated in our center with biliary tree stem cell therapy, we registered no adverse event
but significant benefits.
General significance: The biliary tree stem cell could represent the ideal cell source for the cell therapy of liver
diseases. This article is part of a Special Issue entitled: Cholangiocytes in Health and Diseaseedited by Jesus
Banales, Marco Marzioni, Nicholas LaRusso and Peter Jansen.
1. Introduction
Liver diseases represent a major public health problem affecting
5–15% of the inhabitants worldwide [1]. The final manifestation of
chronic liver diseases is cirrhosis. When a successful etiologic approach
is unavailable or has failed, or delayed, progressive, extensive fibrosis,
with concurrently impaired hepatocyte regeneration, leads to irrever-
sible cirrhosis and then liver failure. Currently, orthotropic liver
transplantation (OLT) is the only therapy for acute and chronic liver
diseases in the terminal stage. However, the number of donated livers is
limited. In addition, OLT cannot be proposed for many cirrhotic pa-
tients, since at very advanced disease stages, surgical risks or other
contraindications exist [2]. Post-surgery complications and rejection
are still significant problems associated with organ transplantation.
Other limitations of OLT relate to the high costs: typically, ~$150,000
to $180,000 for transplant and first-year medical follow-up [2]. These
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limitations drive interests to explore cell therapies aimed to sustain
liver function, to stimulate liver regeneration and to reduce the scarring
process.
2. Cell sources for cell therapy of liver diseases
Different strategies of cell therapy have been so far attempted and
used not only for advanced cirrhosis but also for acute liver failure,
fulminant hepatitis, inborn errors of metabolism, viral hepatitis, liver
toxins, alcohol consumption, chronic cholestatic diseases, auto-
immunity and metabolic disorders such as non-alcoholic steato-hepa-
titis (NASH) [3].
2.1. Adult hepatocytes
The first strategies tried for cell therapies of liver diseases focused
on adult hepatocyte transplantation which was first used for patients
with liver diseases in the 1990s and has continued through for the last
~20 years [4]. The studies have not expanded into large clinical trials
due to difficulties in obtaining high quality donor cells, limitations in
the ability to cryopreserve hepatocytes, and the complications that can
occur with transplantation of the hepatocytes into the liver [4]. These
complications include low engraftment (typically only 5% if trans-
planted via the portal vein), similar engraftment but with bleeding
disorders if transplanted by direct injection, distribution to ectopic sites
(most commonly the lungs), and formation of emboli that can be life
threatening especially if they occur in the lungs [4]. Patients have been
transplanted via the portal vein with isolated hepatocytes at con-
centrations from millions to billions. Immunosuppression was required
in all cases. Although, it is a challenge to draw conclusions from the
published reports, treatments resulted in improved liver functions, but
the patient numbers in each trial are so small that they constitute only
anecdotal evidence of effectiveness [4]. No trials have been done with
sufficient numbers of patients to permit statistical analyses yielding
Model of End-stage Liver Disease (MELD) or Child-Pugh scores, the
standardized metrics used for liver condition. Therapeutic effects were
observed to last from days to a few months and can provide bridging to
a liver transplant [4]. Therapeutic benefits for congenital defects (e.g.
Crigler-Najjar) [5–8] have lasted longer, typically for months and, in a
few cases, up to a few years [8,9]. Leaders in the field have lobbied for
alternate approaches but still retaining a focus on using adult hepato-
cytes [10], but the poor to mediocre results to date have diminished
enthusiasm for this strategy.
2.2. Mesenchymal stem cells and hematopoietic stem cells
Transplantation of mesenchymal stem cells (MSCs) and hemato-
poietic stem cells into patients with liver disease, has resulted in large
numbers of clinical trials throughout the world [11]. At present over 20
clinical trials have been published but with small numbers of patients
(typically under 10). Thus, they are similar to the clinical trials of he-
patocyte transplantation in providing anecdotal evidence or evidence
with minimal possibility of statistically validated findings of the effi-
cacy of the treatments. There are a small number with larger patient
Fig. 1. Human biliary tree stem/progenitor therapy protocol. The isolation protocol involves either the biliary tree from livers of therapeutic abortions or the extrahepatic biliary tree
from donors which are digested mechanically and enzymatically to obtain a cell suspension which is filtered and then subjected to cell immune sorting using EpCAM microbeads. The
EpCAM sorted cells immediately underwent identity test by flow cytometry analysis and microbiological tests before sudden injection into the hepatic artery of patients who have been
admitted to the transplant unit few hours in advance. TO: therapeutic abortion. EpCAM: epithelial adhesion molecule.
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populations such as one reported by Peng et al. [11] involving 53 pa-
tients who underwent a single transplantation with autologous MSCs by
a vascular route via the peripheral vasculature, the spleen or through
the hepatic artery into the liver. The trials comprised treatments with:
a) unfractionated bone marrow or peripheral blood; b) used cytokines
(e.g. granulocyte colony-stimulating factor [G-CSF]) to mobilize cells in
the bone marrow; c) used immune-selected cell populations (CD44+
cells, CD133+ cells) from bone marrow; or d) used cultured MSCs or
cultures treated with growth factors such as hepatocyte growth factor
(HGF), epidermal growth factor (EGF) or fibroblast growth factor
(FGF). Transplantations of any of these forms of MSCs or hematopoietic
stem cells were found to be safe and significantly improved the quality
of life and liver functions [3]. The patient response occurred within
days to weeks, but long-term effects (more than a few months) were not
observed. The conclusions are that effects are due to trophic and im-
mune-modulatory factors. Finally, a single specific molecule secreted by
the MSCs was discovered, the Milk Fat Globule-EGF Factor 8, that
protects against liver fibrosis in mice [12]. Andreone P. et al. [13]
performed a phase I study where 12 patients with end stage liver dis-
ease were reinfused with highly purified CD133+ bone-marrow de-
rived hematopoietic stem cells, after pretreatment with growth factors.
No severe adverse events were registered; MELD worsened during
mobilization in Child Turcotte-C patients. Improvement of liver func-
tion was observed 2 months after reinfusion (MELD 19.5 vs 16;
p= 0.045), 5 patients underwent liver transplantation within
12 months from reinfusion and 2 died because of progressive liver
failure. Again, the benefits were only transient and after a 6-month
follow-up, liver function parameters returned to baseline. A recent
multicenter phase-II open-label controlled trial of repeated autologous
infusions of G-CSF mobilized CD133+ bone marrow stem cells in 27
patients with advanced cirrhosis (versus conservative management or
treatment with G-CSF alone) found no impact on liver function nor on
fibrosis and the trial was interrupted [14]. Therefore, also G-CSF and
purified hematopoietic stem cells did not have an impact on liver
function or fibrosis, according this large, powered, randomized con-
trolled trial [14].
3. Human biliary tree stem cells
In a series of published studies [15–19] and summarized in recent
reviews [20–22], we demonstrated the presence of cells expressing a
variety of endodermal stem cell markers in (peri)-biliary glands (PBGs)
of bile ducts in fetal or adult human tissues. We also found them in
crypts of gallbladder epithelium [16]. The observations in situ in
human biliary tree tissue have been complemented by demonstrations
of culture selection of colonies of stem cells and that expand for months
through self-renewal processes, and are multipotent as indicated by
their ability to lineage restrict to hepatocytes, cholangiocytes or pan-
creatic islet cells depending on the precise conditions to which they are
subjected. Isolation of major subpopulations of hBTSCs from tissues of
all donor ages can be achieved by immunoselection for cells positive for
expression of epithelial cell adhesion molecule (EpCAM). The hBTSCs
constitute approximately 2–4% of the biliary tree cells with the per-
centages varying, depending on which part of the biliary tree is being
analyzed. The richest sites are the large, intrahepatic bile ducts and the
hepato-pancreatic common duct. The hBTSC subpopulations are all
Box 1
Factors potentially affecting the liver engraftment of transplanted cells.
Host factors
• Host liver extracellular matrix:
- major driver of adhesion molecule expression
• Host liver pathologic conditions and related alterations of vasculature perfusion:
- liver engraftment of hHpSCs or hBTSCs increases in the mouse model of CCl4-induced liver fibrosis with respect to normal liver [23,16]
- engraftment and repopulation of transplanted cells have been demonstrated in genetic mice models of liver repopulation, after acute toxic
liver injuries or in mice treated with compounds (retrorsine and monocrotaline) blocking hepatocyte proliferation. These models provide
space for the growth of engrafted cells or a selective advantage for transplanted cells [58]
Factors related to the cell source
• Cell size
• Proliferation:
- hBTSCs have intrinsic proliferative advantages [15,16]; the percentage of hepatic stem cells expressing proliferation markers was on average
45 times greater than the percentage of mature hepatocytes [31]
• Immunogenicity issues:
- fetal hepatic and biliary stem/progenitor cells express no or minimal class I and II MHC antigens (reviewed in [25])
- hBTSCs modulated T-cell apoptosis through the Fas/Fas ligand pathway [25]
• Tolerance to toxins and ischemia:
- high expression of multidrug resistance proteins in stem cells (reviewed in [20] and [21])
Administration routes
• Hepatic delivery:
- via portal vein or hepatic artery or direct injection into the liver
• Ectopic implantation:
- into the peritoneum or into the spleen
Cell rejection: immunomediated cell rejection.
Abbreviations: hHpSCs, human hepatic stem/progenitor cells; hBTSCs, human biliary stem/progenitor cells; CCL4, carbon tetrachloride;
MHC, major histocompatibility complex.
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small (7–9 μm), approximately half the size of mature parenchymal
cells; express various stem cell markers such as endodermal transcrip-
tion factors (SOX9, SOX17, PDX1), pluripotency genes (OCT4, SOX2,
NANOG, SALL4, KLF4/5), CD133 (prominin), CD44 (hyaluronan
receptors), aldehydedehydrogenase (ALDH), and hedgehog proteins
and no markers of mature hepatic or pancreatic cells. They are also
tolerant to ischemia [22]. Preliminary studies indicated that we can
isolate viable and healthy hBTSCs from biliary tree tissue even 48 h or
Box 2
Strategies adopted to increase liver engraftment and repopulation.
Host pre-conditioning (clinical and pre-clinical evidences obtained in hepatocyte transplantation):
• Preparative hepatic irradiation in human and animal models [56]
• Hepatic resection in human and animal models [59]
• Portal vein embolization in animal models [60,61]
Use of matrix components and grafting strategies (pre-clinical studies):
• Preparative injection of fibrin in animal models of hepatocyte transplantation improves the engraftment [32]
• Bio-matrix scaffold components increase proliferation and differentiation of human hepatic stem/progenitor cells in vitro [62]
• Hyaluronic acid-coating increases the engraftment of human biliary tree stem cells in mice w/o damage when injected by vascular route into
portal vein [47]
• Grafting strategies have been devised for transplantation of human hepatic stem cells (hHpSCs) embedded into a mix of soluble signals and
extracellular matrix biomaterials (hyaluronans, type III collagen, laminin): grafted cells remained localized into the livers, resulting in a
larger bolus of engrafted cells in the host livers, with respect to transplantation by direct injection or via a vascular route, under quiescent
conditions and with potential for more rapid expansion under conditions of liver injury [46]
• Combination strategies:
- advanced grafting devices directly transplanted;
- liver scaffold transplantation [63]
Cotransplantation (pre-clinical stages):
• Some evidence exist that cotransplantation of stromal cells facilitates the process of hepatocyte engraftment and proliferation most likely by
the release of cytokines and growth factors in mice [64]
• Pietrosi and co-workers treated 9 patients affected by end-stage liver disease with intrasplenic infusion of a total cell population obtained
from the fetal liver, containing cells expressing typical MSC and HSC markers and found that the procedure was safe and well tolerated with
positive effects on clinical scores and on encephalopathy [28]
Cell sources
• Stem cell therapies of liver diseases with hepatic and biliary stem/progenitor cells are based on favorable biologic properties of stem cells
would improve cell engraftment and repopulation, and attenuate immunoreaction (see refs. [27–29]). However, no clinical trial comparing
different cell types in humans is available.
• In a competitive liver repopulation mouse model (heterozygous alb-uPAtg1/2 mice), engraftment and repopulation capacities of mature
hepatocytes were always superior to early and late hepatoblasts as well as embryonic stem (ES)- and iPS cell-derived cells. Any of the tested
postnatal non-hepatocyte cells, such as hematopoietic stem cells or mesenchymal stromal cells, did not engraft long term and did not
repopulate the liver [58]
Administration route:
• No trial exists in animal models comparing administration via portal vein versus hepatic artery. The former is mainly used for hepatocyte
transplantation, while the latter for hepatic or biliary tree/stem cell transplantation
• Direct injection versus vascular route: directly injected hHpSCs embedded in bio-matrices remained localized into the livers, resulting in a
larger bolus of engrafted cells in the host with respect to transplantation via vascular route [46]
Cell rejection:
• Pharmacology regimens limit immune rejection of human hepatocytes.
• Hepatocytes microencapsulated in alginate limit immunoreaction thanks to the limited access of transplanted cells to host immune cells [65]
• The use of fetal or adult hepatic and biliary stem/progenitor cells alleviated the immunogenicity issues since these cells express no or
minimal class I and II MHC antigens, and since hBTSCs modulated T-cell apoptosis through the Fas/Fas ligand pathway (reviewed in [25]).
No immunosuppression has been required in clinical trials [27,29]
Abbreviations: hHpSCs, human hepatic stem/progenitor cells; hBTSCs, human biliary stem/progenitor cells; CCL4, carbon tetrachloride;
MHC, major histocompatibility complex; MSC, mesenchymal stem cell; HSC, hematopoietic stem cells, ESCs, embryonic stem cells; iPSCs,
induced pluripotent stem cells.
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more after cardiac arrest of the donor [23]. In addition, other pre-
liminary studies suggest that the hBTSCs can be cryopreserved under
serum-free, wholly defined conditions that we established and found
effective for human hepatic stem cells [24].
In preclinical studies, we demonstrated that hBTSCs isolated from
human gallbladder and transplanted in a model of liver cirrhosis
yielded the formation of human hepatocytes and cholangiocytes and,
mostly important, the improvement of the liver function tests in the
model [15].
The hBTSCs can be isolated from fetal or adult livers or from adult
gallbladder. hBTSCs are an ideal source of multipotent endodermal
stem cells with relevant self-renewal and differentiative capacities. In
fact, first, tissues are largely available since fetal biliary trees can be
easily obtained from the fetal liver given the large number of ther-
apeutic abortions, postnatal biliary tree tissues are largely available
since most of the biliary tree is routinely discarded from liver and
pancreatic transplants and gallbladder tissue is readily available given
large numbers of cholecystectomy done routinely. Second, the hBTSCs
can be isolated easily from the biliary tree of any donor age and survive
and expand ex vivo under wholly defined and serum-free conditions
that we established; v) hBTSCs from fetal tissue are non- or minimally
immunogenic given their low or null expression of HLA class I and II
[25] antigens and, therefore, can be transplanted without the need for
immunosuppression; vi) hBTSCs, transplanted into experimental
models of liver cirrhosis, are able to engraft, to differentiate into adult
hepatocytes and cholangiocytes and to rescue liver function. The use of
stem/progenitor cells has advantages over transplantation of mature
hepatocytes. Firstly, stem/progenitor cells, capable of generating ma-
ture liver cells, can circumvent the shortage of hepatocytes. The hBTSCs
are available from hepatic and biliary tree tissues of donors of all ages
and can self-replicate under particular conditions indefinitely. Sec-
ondly, transplanting stem/progenitor cells may, in theory, yield better
long-term repopulation and persistent metabolic activity due to the
constant generation of newly formed mature parenchymal cells.
Thirdly, stem/progenitor cells are not immunogenic [23,26] are more
resistant than adult cells to ischemic damage, and are easier to cryo-
preserve [24]. All of these properties enable stem/progenitors to be a
more robust product for clinical programs.
Khan et al. [27] isolated EpCAM+ cell from the fetal livers and
administered these cells into 25 cirrhotic patients via hepatic artery and
without immunosuppression. The procedure was safe and associated
with significant improvement of liver function that lasted during the
six-month follow up period. This procedure was proven to be safe, as
assessed by ultrasound indicating persistence of echotexture, no focal
lesions, and no abnormal changes in the size of the hepatic artery. Fetal
liver-derived EpCAM+ cells (a mix of human hepatic stem cells/
hHpSCs and hepatoblasts) were marked with Tc99m-hexamethylpro-
pyleneamine oxime and injected; most of the marked cells remained
within the liver lobe. Also, most patients had grade 2 to grade 3 eso-
phageal varices before the transplants, and the majority showed re-
duction in the varices grading. More recently, Pietrosi and co-workers
[28] treated 9 patients affected by end-stage liver disease within
transsplenic infusion of a total cell population obtained from the fetal
liver and found that the procedure was safe and well tolerated with
positive effects on clinical scores and on encephalopathy.
With all these premises, representing a strong rational basis for
translating our preclinical research into a clinical setting, after having
obtained the required authorization, two patients with advanced cir-
rhosis were treated with fetal hBTSC transplantation via hepatic artery
infusion (Fig. 1) [29]. We injected immunoselected EpCAM-positive
cells which also co-expressed Leucine-rich repeat containing G protein-
coupled Receptor 5 (LGR5). In fetal livers, LGR5-positivecells were lo-
cated in the ductal plate and in the epithelium of larger bile ducts [18].
In the gallbladder and hepatic common duct, surface epithelial cells and
bud of PBGs, were diffusely positive for LGR5 [17]. Cell products were
characterized by flow cytometry (FC) for EpCAM and LGR5 before
transplantation (Fig. 1). Estimated cell viability by trypan blue exclu-
sion was routinely higher than 95%. The immunomagnetic sorting re-
sulted in an enrichment of EpCAM-positive cell population to 51% and
contained cells with co-expression of EpCAM and LGR5 (48.4%). Im-
munosorted EpCAM-positive cells were suspended in 10% glucose so-
lution, at a concentration of 1 million cells per ml. The cell suspension
was infused into the hepatic artery at an infusion velocity of 200 ml/h
(Fig. 1). The first patient who received, via the right hepatic artery, 42
million viable EpCAM-sorted cells, showed an evident increasing trend
of serum albumin, associated with a parallel gradual and constant de-
crease of International Normalized Ration (INR). Before treatment, the
patient received repeated hospitalizations, mostly for treatment of as-
cites through large volume paracentesis but their frequency and dura-
tion were significantly shortened by the cell therapy (1-day vs 5-days
hospital stay pre-treatment). The need of paracentesis was abolished
during the follow-up, with no request after cell therapy. The patient
observed the same pharmacological treatment during the whole period
of observation, and did not received albumin injection. Six months after
receiving hBTSC transplantation, the Child-Pugh score decreased from
C-12 to C-10 and the MELD score from 24 to 20, mainly due to im-
provement of coagulation and ascites.
The second patient is a Caucasian female affected by HCV-related
cirrhosis. No side-effects related to the cell infusion were registered
during the scheduled 6-month follow-up. Six months after the treat-
ment, the patient displayed a consistent amelioration of liver function:
Child-Pugh score improved from C-11 to B-8 and the MELD score from
21 to 16. After the 12th month of follow-up the patient continued to
maintain a state of compensated liver cirrhosis. Notably, this patient
experienced a gradual and constant amelioration of albumin value and
coagulation (INR) along 12 months of follow-up. The patient did not
receive intravenous albumin infusion. Exhaustive information on the
different cell sources for cell therapy of liver diseases containing data
on cell origin, number/size/characteristics of clinical trials, vantages/
disadvantages, references, etc., have been included as supplementary
tables (one for cell source) in an updated review published in Stem Cells
by international experts including us and collaborators from Prof. Lola
Reid and Prof. Luca Inverardi groups (see ref. 20).
4. Strategies to ameliorate the engraftment efficiency of hBTSCs
into the liver (see Boxes 1 and 2)
Liver parenchymal repopulation with exogenous cells is a pre-
requisite for a successful cell therapy. Cell translocation from sinusoids
into liver plates requires disruption of the sinusoidal endothelium and
progressive proliferation of the transplanted cells [30] (Box 1). BTSCs
and hepatic stem/progenitor cells (HpSCs) have an intrinsic pro-
liferative advantage when transplanted in liver parenchyma with re-
spect to mature hepatocytes [31] (Box 1). However, the main pitfall of
liver stem cell therapy is the uncertain yield of transplanted cells ef-
fectively grafting in the target organ. Indeed, engraftment efficiencies
of less than 5% were reported for stem cells when delivered by vascular
routes into the livers of primates [32] or in the livers of humans when
injected into the portal vein [33]. That's because the modulation of cell
adhesion and engraftment are key issues in regenerative medicine (Box
1). To this regard, a lot of recent researches focus on strategies to im-
prove grafting efficiency of transplanted cells (Box 2). Hyaluronic acid
(HA) is one of the most utilized biomatrix in human medicine and it
could be one of the best candidates to promote the acceptance of
transplanted cells in the target organs (Box 2). In the last decades,
different evidences showed how extracellular matrix (ECM) plays a
fundamental dynamic role in regulating cell homeostasis. Among the
main ECM components, HA plays a major role because of its biologic,
rheological, viscoelastic and hygroscopic properties [34]. HA molecules
are highly active in interacting each other by forming large polymers or
in association with other molecules [35]. HA is expressed on the cell
surface of both normal and tumor cells, it is an important component of
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the stem cell niche involved in preserving the multipotent character of
stem/progenitor cells, preventing their differentiation and modulating
stem cell migration during embryonic development [36]. Indeed, the
HA matrix supports cell adhesion, growth and differentiation, regulates
cell trafficking and affects various biologic processes including devel-
opment and organogenesis, inflammation, wound healing, and tissue
remodeling [34]. For this reason, many research groups used scaffold/
gel with HA, alone or with other molecules [37–44]. Lozoya et al. [43]
studied the grafting of hHpSC using hydrogel in several concentrations
with thiol-modified HA derivatives, and polyethylene glycol-diacrylate
(PEG-DA), as cross-link. Remarkably, they demonstrate that both the
composition and mechanical properties of the microenvironment can
regulate phenotypic changes. Based on these results obtained in vitro,
Reid L. et al. [46] devised grafting strategies for transplantation of
hHpSCs embedded into a mix of soluble signals and extracellular matrix
biomaterials (hyaluronans, type III collagen, laminin) found in stem cell
niches. Grafted cells remained localized to the livers, resulting in a
larger bolus of engrafted cells in the host livers under quiescent con-
ditions and with potential for more rapid expansion under injured liver
conditions. By contrast, transplantation by direct injection or via a
vascular route resulted in inefficient engraftment and cell spreading to
ectopic sites (Box 2). Recently, we developed a fast and easy method to
coat hBTSCs with HA and assessed the effects of HA-coating on cell
properties in vitro and in vivo [47] (Box 2). The HA coating markedly
improved the viability, colony formation, and population doubling of
hBTSCs in primary cultures, and resulted in a higher expression of in-
tegrins that mediate cell attachment to matrix components. When HA-
coated hBTSCs were transplanted via the spleen into the liver of im-
munocompromised mice, the engraftment efficiency increased to 11%
with respect to 3% of uncoated cells (Box 2). Studies in distant organs
showed minimal ectopic cell distribution without differences between
HA-coated and uncoated hBTSCs and, specifically, cell seeding in the
kidney was excluded. The danger of thrombi generation and ectopic
distribution has been minimized, because the coating process did not
result in large cell clusters. Moreover, the fact that HA is selectively and
actively cleared by the liver could be an additive factor favoring the
selective hepatic engraftment [48]. Finally, HA should create a favor-
able microenvironment allowing a greater number of hBTSCs to engraft
within the liver parenchyma, survive, proliferate, and enhance human
albumin secretion. When, in previous studies, fibrin was tested, instead
of HA, a similar phenomenon was observed [32]. Previous studies
highlighted varied HA trophic effects in different cell systems [49–54].
An especially advantageous aspect of using HAs to facilitate engraft-
ment in condition of liver injury is that they are anti-inflammatory and
entirely biocompatible. In prior studies with the use of HAs for diverse
forms of transplantations, they minimize fibrotic reactions and foster
vascularization that facilitates engraftment [55]. HA is a natural can-
didate for stem cell grafting because it is abundant during embry-
ogenesis, wound repair, and organ regeneration [45]. With regard to
the latter, HA cell coating can be seen as a form of host conditioning,
and it is currently a target to monitor cell rejection in liver cell therapy
in humans [56]. HA coating could improve outcomes of stem cell
therapies of liver diseases and could be immediately translated into the
clinic given that Good Manufactory Practice (GMP)-grade HAs are al-
ready available for clinical use. This molecule indeed is already ap-
proved for clinical use and has been tested in clinical trials [57].
5. Conclusions and perspectives
The improvement of regenerative medicine approaches for liver
diseases requires the identification of sustainable and readily available
cell sources [66]. Other than mature hepatocytes and the different stem
cells already tested in clinics, the possibility of reprogramming adult
somatic cells to generate mature liver cells is attractive [66]. As far as
biliary tissue is concerned, several groups have reportedly defined
protocols to differentiate human induced pluripotent stem cells (iPSCs)
in functional biliary epithelium cells [67–71]. This technology asso-
ciated with dedicated tissue engineering strategies could lead to the
autologous replacement of a damaged biliary tree [67–71]. However,
the clinical application of reprogrammed cells raises concerns due to
the possible uncontrolled tumorigenic expansion within the recipient,
particularly, in long life expectancy situations as in pediatric liver dis-
eases or in chronic liver diseases [66]. In this context, the small mo-
lecule-based reprogramming has raised attention due to its safety [66],
and a recent paper by Wang et al. described a novel approach to gen-
erate human induced endodermal progenitor cells (hiEndoPCs) through
the lineage reprogramming of gastrointestinal epithelial cells induced
by a cocktail of defined small molecules in association with the support
of tissue-specific mesenchymal feeders [72].
Waiting for protocols allowing a safe and effective clinical transla-
tion of iPSCs in regenerative medicine of liver, hBTSCs represent a
ready cellular source. The rationale of “hBTSC treatment of liver cir-
rhosis” is based on these key concepts: i) autochthonous hBTSCs are
normally involved in liver repair but they are impaired in their re-
generation potential and in their capacity to differentiate in mature
liver cells, by the long-lasting inflammatory milieu characterizing liver
cirrhosis; ii) in preclinical studies we demonstrated that isolated fetal
hBTSCs are capable of generating in vitro mature liver cells and that;
iii) hBTSCs, transplanted in a model of liver cirrhosis, yielded the for-
mation of human liver cells (hepatocytes and cholangiocytes) and,
mostly important, the improvement of the liver function tests in the
model, iv) hBTSCs are not immunogenic and are more resistant than
adult cells to ischemic damage; v) in the first two cirrhotic patients
treated in our center, we registered no adverse event but significant
benefits. With these premises, the expectancy is that hBTSC trans-
plantation in patients with advanced liver cirrhosis may yield long-term
repopulation and persistent metabolic activity due to the constant
generation of newly formed mature parenchymal cells and that this
could finally result in improvement of clinically relevant liver func-
tions.
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